Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

The 15 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 95.93, with a low estimate of 48 and a high estimate of 140. The average target predicts an increase of 168.49% from the current stock price of 35.73.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$48	$95.93	$88	$140
Change	+34.34%	+168.49%	+146.29%	+291.83%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	5	6	6	6	6	6
Buy	9	7	7	8	8	8
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	14	14	15	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anupam Rama JP Morgan	JP Morgan	Buy Maintains $104 → $117	Buy	Maintains	$104 → $117	+227.46%	Mar 27, 2025
Allison Bratzel Piper Sandler	Piper Sandler	Buy Maintains $140 → $115	Buy	Maintains	$140 → $115	+221.86%	Mar 17, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $118	Buy	Reiterates	$118	+230.25%	Feb 26, 2025
Ed Arce HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $95	Strong Buy	Reiterates	$95	+165.88%	Feb 18, 2025
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $121 → $136	Strong Buy	Maintains	$121 → $136	+280.63%	Feb 18, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

667.54M

from 560.23M

19.15%

from 560.23M

Revenue Next Year

881.86M

from 667.54M

32.11%

from 667.54M

EPS This Year

-5.21

from -6.29

EPS Next Year

-3.48

from -5.21

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	271.03M	351.41M	363.33M	434.25M	560.23M	667.54M	881.86M	1.32B
Revenue Growth	161.32%	29.66%	3.39%	19.52%	29.01%	19.15%	32.11%	49.23%
EPS	-3.07	-6.70	-10.12	-8.25	-6.29	-5.21	-3.48	-0.26
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	22	21	15

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	700.1M	1.1B	2.0B
Avg	667.5M	881.9M	1.3B
Low	623.9M	695.5M	794.3M

Revenue Growth

Revenue Growth	2025	2026	2027
High	25.0%	59.7%	121.8%
Avg	19.2%	32.1%	49.2%
Low	11.4%	4.2%	-9.9%

EPS Forecast

EPS	2025	2026	2027
High	-2.34	-0.23	5.89
Avg	-5.21	-3.48	-0.26
Low	-6.02	-5.42	-3.73

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.